EC

New Thermal Printheads from ROHM Deliver the Industry's Fastest Print Speed for Barcode Labels

Retrieved on: 
Wednesday, October 11, 2023
Printing, Static electricity, EC, Growth, Heat, 3D, Rohm, ROHM, Corrosion, Warehouse, Printed circuit board

Santa Clara, CA and Kyoto, Japan, Oct. 11, 2023 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced the TE2004-QP1W00A / TE3004-TP1W00A high-speed, highly reliable thermal printheads, optimized for barcode label printers applied in logistics and inventory management.

Key Points: 
  • Santa Clara, CA and Kyoto, Japan, Oct. 11, 2023 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced the TE2004-QP1W00A / TE3004-TP1W00A high-speed, highly reliable thermal printheads, optimized for barcode label printers applied in logistics and inventory management.
  • In recent years, the growth of the e-commerce (EC) market and diversifying customer needs have increased the demand for logistics and inventory management labels.
  • Conventional thermal printheads, however, are limited to printing speeds ranging from 250mm/s to 300mm/s.
  • In response, ROHM developed the industry’s fastest [1] high speed and highly reliable thermal printheads that leverage novel structures and technologies.

Kyowa Kirin to Acquire Orchard Therapeutics

Retrieved on: 
Thursday, October 5, 2023
Acquisition, HSC, Therapy, Stem cell, Vision, Health, Research, Priority review, Morrison, Sanfilippo syndrome, Food and Drug Administration Amendments Act of 2007, DSM-IV codes, Kyowa Kirin, Frontotemporal dementia, EC, JST, MLD, Civil service commission, Health care, Food, European Commission, Biotechnology, Transaction, FDA, CVR, FTD, MPS, Guggenheim Partners, Kirin, Sanfilippo, TSE, ADS, MHRA, Morrison & Foerster, Science, PDUFA, Life, Patient, Communications satellite, Pharmaceutical industry, Vaccine, Security (finance), Orchard, Atidarsagene autotemcel

TOKYO and LONDON and BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, and Orchard Therapeutics plc (Orchard Therapeutics, Nasdaq: ORTX), a global gene therapy leader, today announced the companies have entered into a definitive agreement under which Kyowa Kirin will acquire Orchard Therapeutics for $16.00 per American Depositary Share (ADS) in cash (approximately $387.4 million, or ¥57.3 billion), under which Orchard shareholders will hold an additional contingent value right (CVR) of $1.00 per ADS. An additional $1.00 CVR will be paid for a total of $17.00 per ADS, or approximately $477.6 million (¥70.7 billion) if the conditions are met.

Key Points: 
  • Kyowa Kirin has established a 2030 Vision to consistently create and deliver medicines with life-changing value that ultimately makes people smile, as a J-GSP.
  • “We are excited to announce that we have signed the Transaction Agreement to acquire Orchard Therapeutics, one of the leading providers of HSC gene therapy,” said Takeyoshi Yamashita, Ph.D., Director of the Board, chief medical officer, senior managing executive officer of Kyowa Kirin.
  • Under the terms of the agreement, Kyowa Kirin will initiate a scheme of arrangement to acquire all Orchard Therapeutics’ ADSs at a price of $16.00 per ADS in cash (or aggregated value of approximately $387.4 million, or approximately ¥57.3 billion) at closing, which represents a premium of 144% to Orchard Therapeutics’ volume-weighted average price per ADS over the previous 30 days ended October 4.
  • Following the completion of the acquisition, Orchard Therapeutics will become a wholly-owned subsidiary of Kyowa Kirin.

European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy

Retrieved on: 
Monday, October 16, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, DFS, MRK, NYSE, Lung cancer, American Joint Committee on Cancer, European Directive on Traditional Herbal Medicinal Products, Death, NSCLC, Rated R, AJCC, Committee for Medicinal Products for Human Use, Risk, European Commission, Recurrence, Disease, Merck & Co., Immunotherapy, EC, II, Marketing, Committee, Civil service commission, Face, Patient, Pharmaceutical industry, Merck, EU

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with non-small cell lung cancer (NSCLC) who are at high risk of recurrence following complete resection and platinum-based chemotherapy.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a monotherapy for the adjuvant treatment of adults with non-small cell lung cancer (NSCLC) who are at high risk of recurrence following complete resection and platinum-based chemotherapy.
  • This approval by the EC follows the positive recommendation from the Committee for Medicinal Products for Human Use received in September 2023 and was based on results from the Phase 3 KEYNOTE-091 trial.
  • At a median follow up time of 46.7 months, KEYTRUDA demonstrated a clinically meaningful improvement in disease-free survival (DFS) in patients who received adjuvant chemotherapy, reducing the risk of disease recurrence or death by 24% (HR=0.76 [95% CI, 0.64-0.91]).
  • “We are proud that in Europe, KEYTRUDA now has five approved indications in non-small cell lung cancer, in both earlier and advanced stages of disease.”

Mundipharma and Cidara Therapeutics receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults1

Retrieved on: 
Friday, October 13, 2023
Health, Infectious Diseases, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, European, Multimedia, Infection, Restore, Committee for Medicinal Products for Human Use, CHMP, Fungal infection, European Medicines Agency, CDTX, Mortality, European Commission, Safety, Disease, EMA, Medical Mycology, FDA, Therapy, Phase, EC, Mycology, Committee, News, Candidiasis, Civil service commission, Caspofungin, Patient, Vaccine, Pharmaceutical industry, Mundipharma

Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.1

Key Points: 
  • Mundipharma and Cidara Therapeutics (Nasdaq: CDTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for rezafungin (rezafungin acetate) for the treatment of invasive candidiasis in adults.1
    This press release features multimedia.
  • A new treatment option for these serious infections is a much-needed addition.”
    “We would like to thank the CHMP for their careful consideration of the use of rezafungin.
  • The CHMP’s positive opinion on rezafungin for the treatment of serious fungal infections, such as invasive candidiasisin adults, will be referred to the European Commission (EC), which will deliver a final decision in approximately two months.
  • Cidara Therapeutics has partnered with Mundipharma, which has commercial rights to rezafungin outside the U.S. and Japan.

ESMA consults on the potential impact of shortening the standard settlement cycle

Retrieved on: 
Tuesday, October 17, 2023
European Securities and Markets Authority, European, CFE, Rural sociology, Civil service commission, T+1, EC, European Commission, ESMA, Security (finance), EU

ESMA consults on the potential impact of shortening the standard settlement cycle

Key Points: 
  • ESMA consults on the potential impact of shortening the standard settlement cycle
    The European Securities and Markets Authority (ESMA), the EU’s financial markets regulator and supervisor, today launches a Call for Evidence (CfE) on the shortening of the settlement cycle.
  • The Call for Evidence will help ESMA to assess the costs and benefits of a possible reduction of the settlement cycle in the European Union (EU); and identify whether any regulatory action is needed to smoothen the impact for EU market participants of the planned shortening of the settlement cycle to T+1 in other jurisdictions, such as the US.
  • ESMA seeks input, including quantitative evidence, from all stakeholders involved in financial markets, and not only those in financial market infrastructures.
  • ESMA may provide an earlier report to the EC identifying possible regulatory actions to address the impact for EU market participants of the US move to T+1.

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Retrieved on: 
Tuesday, October 10, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, NYSE, Abstract, Breast cancer, Brentuximab vedotin, INT, Trastuzumab, RCC, Survival, Endometrial cancer, PEM, NRG, ESMO, Merck & Co., Webcast, Belzutifan, European Society for Medical Oncology, ADC, Research, TUC, KRAS, Lung cancer, RAS, AstraZeneca, EC, Adenocarcinoma, Head, TNBC, MRK, Pembrolizumab, Everolimus, CRC, Cancer, Olaparib, EFS, Quality of life (healthcare), SWOG, Congress, LBA32, LBA21, PBO, Chemoradiotherapy, CP, Safety, MBC, Patient, Pharmaceutical industry, Birth control, Medical imaging, Animal feed, Vaccine, Tras, Merck, NSCLC, Eisai

The event will take place virtually and will be accessible via webcast.

Key Points: 
  • The event will take place virtually and will be accessible via webcast.
  • Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC.
  • Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801.
  • mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response.

Ecopetrol reports that Luis Felipe Rivera has been appointed as Vice President of Science, Technology, and Innovation

Retrieved on: 
Saturday, October 14, 2023
Permian, ISA, MBA, NYSE, Acquisition, Innovation, ICT, Transport, Administration, Behavior, Systems engineering, EC, Growth, Limited jurisdiction, Gulf of Mexico, Industrial University of Santander, BVC, XM, Board on Science, Technology, and Economic Policy, Information technology, Specialization, Telecommunications, Drug

-----------------------------------------

Key Points: 
  • BOGOTÁ, Colombia, Oct. 14, 2023 /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) informs that the Board of Directors, during its meeting held on October 13, 2023, appointed Luis Felipe Rivera as the Vice President of Science, Technology, and Innovation, effective from October 23, 2023.
  • Dr. Rivera holds a degree in Systems Engineering from Universidad Industrial de Santander, a specialization in Administration from Universidad ICESI, and is currently pursuing an MBA at Universidad Adolfo Ibáñez in Miami.
  • This press release contains business prospect statements, operating and financial result estimates, and statements related to Ecopetrol's growth prospects.
  • We do not intend and do not assume any obligation to update these forward-looking statements.

Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant)

Retrieved on: 
Friday, October 13, 2023
Health, Health care, Hot, Astellas Pharma, Committee for Medicinal Products for Human Use, CHMP, European, Fezolinetant, The Journal of Clinical Endocrinology and Metabolism, TSE, European Commission, Medication, Safety, European Medicines Agency, NKB, BRIGHT, EMA, MHRA, VMS, EC, Journal, Committee, Metabolism, Obstetrics and gynaecology, Gynaecology, Menopause, Civil service commission, Woman, Lancet, Hypothalamus, Pharmaceutical industry, Medical device

TOKYO, Oct. 13, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on October 12 adopted a positive opinion relating to the use of VEOZA™ (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.4 VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause.5,6  

Key Points: 
  • "Today's positive CHMP opinion marks another significant milestone for both fezolinetant and women's health.
  • We are excited to be another step closer to potentially providing a novel and important treatment option to individuals in Europe suffering from moderate to severe VMS associated with menopause."
  • The positive CHMP opinion is based on the results from the BRIGHT SKY™ program, which included three Phase 3 clinical trials that collectively enrolled over 3,000 individuals across Europe, the U.S. and Canada.
  • Astellas has already reflected the impact from this result in its financial forecast of the current fiscal year ending March 31, 2024.

HUBER+SUHNER introduces lead-free radio frequency SMA connectors in boost to product sustainability

Retrieved on: 
Monday, October 9, 2023
Health, Transport, Alloy, Safety, Restriction of Hazardous Substances Directive, SVHC, Workforce, Ecology, EC, Environment, Return loss, Radio, Lead, SMA, SK, Cable television, Printed circuit board, Communication, Aviation, EU

HERISAU, Switzerland, Oct. 9, 2023 /PRNewswire/ -- HUBER+SUHNER is proud to be one of the first companies in the electronic connectivity sector to launch a lead-free solution for its radio frequency (RF) SMA connectors. These eco-friendly connectors are available for order immediately via its distributor network.

Key Points: 
  • HERISAU, Switzerland, Oct. 9, 2023 /PRNewswire/ -- HUBER+SUHNER is proud to be one of the first companies in the electronic connectivity sector to launch a lead-free solution for its radio frequency (RF) SMA connectors.
  • Their engineers have now devised a lead-free solution for connectors that can deliver the same levels of electrical performance as conventional connectors.
  • By introducing a lead-free SMA connector solution, HUBER+SUHNER is staying several steps ahead of, and fulfilling every aspect of these changing regulations.
  • The company serves the three main markets Industry, Communication and Transportation with applications from the three technologies of radio frequency, fiber optics and low frequency.

HUBER+SUHNER introduces lead-free radio frequency SMA connectors in boost to product sustainability

Retrieved on: 
Monday, October 9, 2023
Health, Transport, Alloy, Safety, Restriction of Hazardous Substances Directive, SVHC, Workforce, Ecology, EC, Environment, Return loss, Radio, Lead, SMA, SK, Cable television, Printed circuit board, Communication, Aviation, EU

HERISAU, Switzerland, Oct. 9, 2023 /PRNewswire/ -- HUBER+SUHNER is proud to be one of the first companies in the electronic connectivity sector to launch a lead-free solution for its radio frequency (RF) SMA connectors. These eco-friendly connectors are available for order immediately via its distributor network.

Key Points: 
  • HERISAU, Switzerland, Oct. 9, 2023 /PRNewswire/ -- HUBER+SUHNER is proud to be one of the first companies in the electronic connectivity sector to launch a lead-free solution for its radio frequency (RF) SMA connectors.
  • Their engineers have now devised a lead-free solution for connectors that can deliver the same levels of electrical performance as conventional connectors.
  • By introducing a lead-free SMA connector solution, HUBER+SUHNER is staying several steps ahead of, and fulfilling every aspect of these changing regulations.
  • The company serves the three main markets Industry, Communication and Transportation with applications from the three technologies of radio frequency, fiber optics and low frequency.